Dilated cardiomyopathy (DCM) is best understood as the final common response of myocardium to diverse genetic and environmental insults. A rigorous work-up can exclude alternative causes of left ventricular (LV) dilation and dysfunction, identify etiologies that may respond to specific treatments, and guide family screening. A significant proportion of DCM cases have an underlying genetic or inflammatory basis. Measurement of LV size and ejection fraction remain central to diagnosis, risk stratification, and treatment, but other aspects of cardiac remodeling inform prognosis and carry therapeutic implications. Assessment of myocardial fibrosis predicts both risk of sudden cardiac death and likelihood of LV functional recovery, and has significant potential to guide patient selection for cardioverter-defibrillator implantation.
. Until recently, the evaluation of DCM has scarcely deviated from the standard approach to systolic HF. However, advanced imaging techniques, together with modern genetic, biomarker, and biopsy analysis, increasingly allow for more rigorous assessment of etiology and cardiac remodeling, as well as earlier disease detection. In this review, we examine the role of a more detailed approach to DCM in contemporary practice and its emerging potential to guide individualized treatment strategies.
PART 1: EVALUATION OF ETIOLOGY
Before diagnosing DCM, it is necessary to exclude conditions with phenotypic overlap. Thereafter, identification of a specific underlying etiology may allow targeted disease-specific treatment, guide the need for family screening, or inform prognosis.
EXCLUSION OF OTHER CAUSES. Ischemic cardiomyopathy is conventionally distinguished from DCM by the presence of $75% stenosis in the left main stem, proximal left anterior descending artery, or 2 or more epicardial coronary arteries on invasive or computed tomography coronary angiography (2) . Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) provides an alternative approach and may identify prior myocardial infarction (subendocardial or transmural LGE) in as many as 13% of patients with suspected DCM and unobstructed coronary arteries (3) . In addition to ischemic cardiomyopathy, DCM must also be distinguished from other nonischemic cardiomyopathies and physiological adaptations that may generate similar patterns of LV remodeling ( Table 2) .
ROUTINE ETIOLOGICAL WORK-UP. A suggested etiological evaluation for patients with DCM is listed in Table 1 . Regular alcohol consumption of at least 80 g/day for over 5 years has frequently been associated with LV dilation and dysfunction (4) . Anthracycline histology-confirmed cases, the reported incidence of DCM varies between 14% and 52% (6).
CMR enables noninvasive detection of myocarditis through 3 combined tissue characterization techniques ("Lake Louise criteria") ( Figures 1E and 1F (10) . Limited data also suggest potential benefit from antiviral therapy with interferon-beta in patients with persistent cardiotropic viruses (11) . departure from previous consensus statements (8, 13) and international HF guidelines (14, 15) . For now, a rational approach to this conflicting guidance is to also recommended for first-degree relatives of patients with apparently idiopathic DCM.
At present, routine genetic testing is only recommended in familial disease ($2 affected family members) (15) , where its diagnostic yield is 30% to 35%. Currently, the identification of a causal mutation carries few implications for prognosis or treatment of the index case, and the principal rationale for Japp et al.
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The Diagnosis and Evaluation of DCM The Diagnosis and Evaluation of DCM In a recent meta-analysis of SCD risk stratification techniques in DCM, several LV remodeling and The Notably, this meta-analysis did not include LGE-CMR, which has been shown to predict arrhythmic outcomes in DCM in multiple studies (29, 31, (43) (44) (45) . We previously showed that myocardial fibrosis identified by LGE-CMR is an independent predictor of SCD risk and all-cause mortality, providing prognostic information that is incremental to LVEF (31). These findings have since been corroborated by a meta-analysis incorporating 1,488 DCM patients (46) . In DCM patients undergoing guideline-directed ICD implantation for primary prevention, the presence of LGE is associated with a hazard ratio of 10 to 15 for subsequent SCD or appropriate ICD therapy (43) .
Conversely, the absence of midwall LGE identifies a population of DCM patients at low risk of SCD, even when LVEF is #35%. The combination of LGE-CMR with biomarker analysis may offer even greater discriminatory power, identifying an "ultra-low" risk of arrhythmic outcomes (e.g., 1% to 3%/year) among DCM patients who meet current criteria for ICD implantation (45). Regenerate:
• Stem cell therapy
• 'Bridge to recovery' LV assist device
Replace:
• Cardiac transplant
• 'Destination therapy' LV assist device
Reverse remodeling:
• Neurohormonal blockade The Diagnosis and Evaluation of DCM The Diagnosis and Evaluation of DCM J U N E 2 8 , 2 0 1 6 : 2 9 9 6 -3 0 1 0 first-degree relatives of DCM patients who lack a clear underlying etiology. As DCM exhibits age-dependent penetrance, repeated screening is advocated (e.g., every 2 to 5 years until 50 to 60 years of age) to detect late-onset disease (47, 48) . Identification of a pathogenic gene mutation rationalizes screening by allowing mutation-specific cascade testing of family members. Relatives without the mutation can be LGE-CMR can detect myocardial replacement fibrosis prior to overt LV remodeling in patients with laminopathy or Becker's muscular dystrophy (53, 54) .
However, the assessment of diffuse interstitial fibrosis ( Figure 2C 
